Table 2.
Immunogenicity data of GeneVac-B, Engerix B and Shanvac B in babies born to HBsAg positive mothers
| Parameters | 1st dose | 2nd dose | 3rd dose | After one year |
| Group-I- GeneVac-B | ||||
| No. of infants | 58 | 48 | 48 | 35 |
| Seroconversion | 57.10% | 94.20% | 100% | 100% |
| Seroprotection | 22.80% | 82.80% | 100% | 100% |
| GMT (mIu/mL) | 11.6 | 35.4 | 93.5 | 226.7 |
| Group-II- Engerix B | ||||
| No. of infants | 50 | 43 | 38 | 21 |
| Seroconversion | 57.10% | 90.00% | 100% | 100% |
| Seroprotection | 19.00% | 71.40% | 100% | 100% |
| GMT (mIu/mL) | 8.4 | 24.4 | 80.9 | 197.9 |
| Group-III Shanvac B | ||||
| No. of infants | 50 | 45 | 32 | 12 |
| Seroconversion | 50% | 91.60% | 100% | 100% |
| Seroprotection | 16.60% | 66.60% | 100% | 100% |
| GMT (mIu/mL) | 8 | 18.6 | 72.55 | 173.6 |